Equities research analysts at StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Akari Therapeutics Stock Performance
Shares of NASDAQ AKTX opened at $2.78 on Friday. The business’s 50-day moving average price is $3.01 and its two-hundred day moving average price is $2.77. Akari Therapeutics has a one year low of $1.08 and a one year high of $4.40.
About Akari Therapeutics
Read More
- Five stocks we like better than Akari Therapeutics
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Energy Vault Soars 100%: CEO Shares Why in MarketBeat Exclusive
- Investing In Preferred Stock vs. Common Stock
- Meta’s Q3 Earnings Beat—Is This Dip a Golden Entry Opportunity?
- Investing in the High PE Growth Stocks
- Top Nuclear Stocks Thriving on Soaring Energy Demand
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.